The Ncardia team had a great week in Brussels. There was a lot of excitement around efforts to speed and improve cell and gene therapy campaigns, and we had many in-depth conversations with clients and prospects about Ncardia’s ability to bring human biology into discovery at a much earlier stage than traditionally possible.
Much of the discussion focused how testing on human in vitro models help with validation of vector selectivity, prediction of vector toxicity and inflammation, transduction efficiency, and the ability to assess the efficacy of gene therapies with functional readouts. Gene therapy developers were also attracted to the potential Ncardia’s approach offers to reduce the number of animals required for preclinical testing.
Our poster presentations also garnered a good bit of attention. Space and time to view these was limited, so if you didn’t get a chance to see them in Brussels, we’ve made them available for download:
- Human induced pluripotent stem cell-derived models as a platform to advance AAV testing with high confidence
-
Evaluating the transduction efficiency of different AAV serotypes on hiPSC-derived cardiomyocytes
And if any of this sparks ideas or questions about your own work, don't hesitate to contact us.
